ReviewNature reviews. Urology2022
Current and emerging treatment options for premature ejaculation.
Review in Nature reviews. Urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Efficacy and safety of botulinum toxin-A injection in the treatment of premature ejaculation: A systematic review and meta-analysis.PloS one · 2025Pooled it
- Clinical Efficacy and Safety of Botulinum Toxin A Injection into the Bulbospongiosus Muscle for Treating Lifelong Premature Ejaculation: A Systematic Review and Meta-Analysis.American journal of men's healthPooled it
- The Effects of Steady Freddy, a Lidocaine-Based Pump Spray for the Treatment of Premature Ejaculation (PE).American journal of men's healthTrial
- Association of sexual dysfunctions according to DSM-5 criteria with structural brain differences in women and men from the Hamburg City Health Study.Dialogues in clinical neuroscience · 2026Article
- Article
- Beyond neurotransmission: the roles of serotonylation in physiological and pathological processes.Cellular & molecular biology letters · 2026Review
- Article
- On-demand silodosin 4 mg vs dapoxetine 60 mg in treatment of primary premature ejaculation: A prospective randomized study.Arab journal of urology · 2026Article
- Evaluating the Role of Subcoronal Botulinum Toxin Injection in the Management of Premature Ejaculation.Clinical medicine insights. Case reports · 2026Article
- Assessing neurobiology of lifelong premature ejaculation through brain MRI structural similarity gradient.European radiology experimental · 2025Article
- The Association Between Premature Ejaculation and Non-Dipper Blood Pressure: A Cross-Sectional Study.Journal of clinical medicine · 2025Article
- Management and treatment variations in premature ejaculation: a nationwide survey by the Andrology Working Group of the Society of Urological Surgery in Turkey.International urology and nephrology · 2025Article
- Abnormal grey matter in identifying primary intravaginal anejaculation patients from healthy controls: a voxel-based morphometry analysis.Sexual medicine · 2025Article
- Global Andrology Forum Clinical Practice Guidelines on the Management of Premature Ejaculation.The world journal of men's health · 2025Article
- Article
- Article
- Development and in vitro/in vivo evaluation of taste-masked orodispersible films of dapoxetine hydrochloride using ion exchange resins.Drug delivery and translational research · 2025Article
- British Society for Sexual Medicine (BSSM) Position Statement on Premature Ejaculation.The world journal of men's health · 2025Review
- Examining adherence to American Urological Association (AUA) guidelines in men's health: Insights from the New York section AUA survey.Investigative and clinical urology · 2025Article
- Integrative Analysis of Drug Co-Prescriptions in Peritoneal Dialysis Reveals Molecular Targets and Novel Strategies for Intervention.Journal of clinical medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Premature ejaculation (PE) is a prevalent male sexual dysfunction. Current standard treatment regimens include behavioural therapies, topical anaesthetics, dapoxetine and other selective serotonin reuptake inhibitors (SSRIs). Most of the pharmacotherapeutic options target neurotransmitters (such as serotonin and oxytocin) that have a role in the ejaculation mechanism. However, these treatments are mildly effective and only provide a temporary delay in the ejaculation latency time, and PE recurs when the treatment is stopped. Thus, a treatment for PE is urgently needed and research is ongoing to find the ideal PE therapy. The efficacy and safety of topical anaesthetics and SSRIs in delaying ejaculation have been confirmed in many well-designed controlled trials. Both preclinical and clinical studies on new-generation SSRIs are ongoing. Moreover, promising results came from clinical trials in which the efficacy of on-demand PE therapies targeting neurotransmitters other than serotonin, such as α1-adrenoceptor antagonists and oxytocin antagonists, was assessed. Surgical intervention and neuromodulation have been proposed as potential treatment options for PE; however, current PE guidelines do not recommend these treatments owing to safety concerns.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.